Screener
BioMarin Pharmaceuticals BMRN PP&E (Net)
PP&E (Net) at other companies
Segments
By geography
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| ASSETS | June 30, 2026 / (unaudited) | December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Total current assets | 3,971,623 | 3,953,490 |
| Noncurrent assets: | ||
| Long-term investments | — | 492,242 |
| Property, plant and equipment, net | 989,994 | 952,508 |
| Intangible assets, net | 4,879,367 | 213,837 |
| Goodwill | 655,745 | 196,199 |
| Deferred tax assets | 888,575 | 1,508,697 |
| Other assets | 338,138 | 277,049 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's PP&E (net)?
- BioMarin Pharmaceuticals (BMRN) reported PP&E (net) of $989.99M in Q2 2026.
- How has BioMarin Pharmaceuticals's PP&E (net) changed year-over-year?
- BioMarin Pharmaceuticals's PP&E (net) decreased by 3.9% year-over-year, from $1.03B to $989.99M.
- What is the long-term trend for BioMarin Pharmaceuticals's PP&E (net)?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's PP&E (net) has grown at a -1.6% compound annual growth rate (CAGR), from $1.03B to $952.51M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about BioMarin Pharmaceuticals's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude